Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D HART

Showing results (621-630 of 623) with videos related to

Pageof 63
Sort By:
You have reached the last page of results.This site can display upto 623 results.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Nature Communications|February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatientsJoseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 63

Showing results (621-630 of 623) with videos related to

Sort By:
Pageof 63
You have reached the last page of results.This site can display upto 623 results.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Nature Communications|February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatientsJoseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 63